The study by Papaemmanuil et al. revealed that 73% (319 of 436) of NPM1-mutated AML patients are positive for mutations in at least one of the following genes: DNMT3A, IDH1, IDH2, and TET2 [5]. This evidence concerns the gene IDH2 and acute myeloid leukemia.